Sotatercept is Now in Active Negotiation at pCPA

There has been significant progress in making sotatercept available to those who need it. Just two months after Health Canada approved it last August, Canada's Drug Agency recommended that it be publicly funded. Since then, however, it has been in limbo, waiting for provinces to begin price negotiations through the pan-Canadian Pharmaceutical Alliance (pCPA).

Our Time Matters PAH advocacy campaign has been urging the pCPA to prioritize these negotiations, and as of April 2, sotatercept is officially in active negotiation. This is a crucial step forward for pulmonary arterial hypertension (PAH) patients waiting for better treatment options.

We encourage all provinces to move quickly in finalizing these negotiations so that sotatercept can become accessible without further delay. PAH clinicians need this treatment to provide the best possible care, and patients cannot afford to wait.